These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 33271136)
1. Extended Characterization and Impact of Visible Fatty Acid Particles - A Case Study With a mAb Product. Saggu M; Demeule B; Jiang L; Kammerer D; Nayak PK; Tai M; Xiao N; Tomlinson A J Pharm Sci; 2021 Mar; 110(3):1093-1102. PubMed ID: 33271136 [TBL] [Abstract][Full Text] [Related]
2. Fatty Acids Can Induce the Formation of Proteinaceous Particles in Monoclonal Antibody Formulations. Zhang J; He J; Smith KJ J Pharm Sci; 2022 Mar; 111(3):655-662. PubMed ID: 34666046 [TBL] [Abstract][Full Text] [Related]
3. Identification of Subvisible Particles in Biopharmaceutical Formulations Using Raman Spectroscopy Provides Insight into Polysorbate 20 Degradation Pathway. Saggu M; Liu J; Patel A Pharm Res; 2015 Sep; 32(9):2877-88. PubMed ID: 25773722 [TBL] [Abstract][Full Text] [Related]
4. Polysorbate Degradation and Particle Formation in a High Concentration mAb: Formulation Strategies to Minimize Effect of Enzymatic Polysorbate Degradation. Roy I; Patel A; Kumar V; Nanda T; Assenberg R; Wuchner K; Amin K J Pharm Sci; 2021 Sep; 110(9):3313-3323. PubMed ID: 34077768 [TBL] [Abstract][Full Text] [Related]
5. Free fatty acid particles in protein formulations, part 2: contribution of polysorbate raw material. Siska CC; Pierini CJ; Lau HR; Latypov RF; Fesinmeyer RM; Litowski JR J Pharm Sci; 2015 Feb; 104(2):447-56. PubMed ID: 25196966 [TBL] [Abstract][Full Text] [Related]
6. Polysorbate 20 Degradation in Biopharmaceutical Formulations: Quantification of Free Fatty Acids, Characterization of Particulates, and Insights into the Degradation Mechanism. Tomlinson A; Demeule B; Lin B; Yadav S Mol Pharm; 2015 Nov; 12(11):3805-15. PubMed ID: 26419339 [TBL] [Abstract][Full Text] [Related]
7. Dissolution of Polysorbate 20 Degradation Related Free Fatty Acid Particles in Intravenous Bag Solutions. Doshi N; Rutherford K; Najjar A J Pharm Sci; 2021 Feb; 110(2):687-692. PubMed ID: 33039438 [TBL] [Abstract][Full Text] [Related]
8. Understanding Particle Formation: Solubility of Free Fatty Acids as Polysorbate 20 Degradation Byproducts in Therapeutic Monoclonal Antibody Formulations. Doshi N; Demeule B; Yadav S Mol Pharm; 2015 Nov; 12(11):3792-804. PubMed ID: 26419285 [TBL] [Abstract][Full Text] [Related]
9. Improving Prediction of Free Fatty Acid Particle Formation in Biopharmaceutical Drug Products: Incorporating Ester Distribution during Polysorbate 20 Degradation. Doshi N; Martin J; Tomlinson A Mol Pharm; 2020 Nov; 17(11):4354-4363. PubMed ID: 32941040 [TBL] [Abstract][Full Text] [Related]
10. A Comprehensive Assessment of All-Oleate Polysorbate 80: Free Fatty Acid Particle Formation, Interfacial Protection and Oxidative Degradation. Doshi N; Giddings J; Luis L; Wu A; Ritchie K; Liu W; Chan W; Taing R; Chu J; Sreedhara A; Kannan A; Kei P; Shieh I; Graf T; Hu M Pharm Res; 2021 Mar; 38(3):531-548. PubMed ID: 33713012 [TBL] [Abstract][Full Text] [Related]
11. Free fatty acid particles in protein formulations, part 1: microspectroscopic identification. Cao X; Fesinmeyer RM; Pierini CJ; Siska CC; Litowski JR; Brych S; Wen ZQ; Kleemann GR J Pharm Sci; 2015 Feb; 104(2):433-46. PubMed ID: 25175016 [TBL] [Abstract][Full Text] [Related]
12. A Newly Identified Impurity in Polysorbate 80, the Long-Chain Ketone 12-Tricosanone, Forms Visible Particles in a Biopharmaceutical Drug Product. Hampl V; Guo X; Ehrenstrasser C; Viertler M; Rayner L; Campanelli G; Schipflinger R; Thewes K; Cerreti A; Boehm S; Sonderegger C J Pharm Sci; 2018 Jun; 107(6):1552-1561. PubMed ID: 29499279 [TBL] [Abstract][Full Text] [Related]